The expert panel offers comprehensive insights on the patient journey for people with Alzheimer disease, highlighting symptoms, challenges, and the diagnostic process.
RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis
June 19th 2025Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.
Read More